Tags

Type your tag names separated by a space and hit enter

Coagulopathies after Vaccination against SARS-CoV-2 May Be Derived from a Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Triggered Signaling Pathways.
Int J Mol Sci. 2021 Oct 06; 22(19)IJ

Abstract

Novel coronavirus SARS-CoV-2 has resulted in a global pandemic with worldwide 6-digit infection rates and thousands of death tolls daily. Enormous efforts are undertaken to achieve high coverage of immunization to reach herd immunity in order to stop the spread of SARS-CoV-2 infection. Several SARS-CoV-2 vaccines based on mRNA, viral vectors, or inactivated SARS-CoV-2 virus have been approved and are being applied worldwide. However, the recent increased numbers of normally very rare types of thromboses associated with thrombocytopenia have been reported, particularly in the context of the adenoviral vector vaccine ChAdOx1 nCoV-19 from Astra Zeneca. The statistical prevalence of these side effects seems to correlate with this particular vaccine type, i.e., adenoviral vector-based vaccines, but the exact molecular mechanisms are still not clear. The present review summarizes current data and hypotheses for molecular and cellular mechanisms into one integrated hypothesis indicating that coagulopathies, including thromboses, thrombocytopenia, and other related side effects, are correlated to an interplay of the two components in the vaccine, i.e., the spike antigen and the adenoviral vector, with the innate and immune systems, which under certain circumstances can imitate the picture of a limited COVID-19 pathological picture.

Authors+Show Affiliations

Syntacoll GmbH, 93342 Saal an der Donau, Germany.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

34639132

Citation

Kircheis, Ralf. "Coagulopathies After Vaccination Against SARS-CoV-2 May Be Derived From a Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Triggered Signaling Pathways." International Journal of Molecular Sciences, vol. 22, no. 19, 2021.
Kircheis R. Coagulopathies after Vaccination against SARS-CoV-2 May Be Derived from a Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Triggered Signaling Pathways. Int J Mol Sci. 2021;22(19).
Kircheis, R. (2021). Coagulopathies after Vaccination against SARS-CoV-2 May Be Derived from a Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Triggered Signaling Pathways. International Journal of Molecular Sciences, 22(19). https://doi.org/10.3390/ijms221910791
Kircheis R. Coagulopathies After Vaccination Against SARS-CoV-2 May Be Derived From a Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Triggered Signaling Pathways. Int J Mol Sci. 2021 Oct 6;22(19) PubMed PMID: 34639132.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Coagulopathies after Vaccination against SARS-CoV-2 May Be Derived from a Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Triggered Signaling Pathways. A1 - Kircheis,Ralf, Y1 - 2021/10/06/ PY - 2021/09/08/received PY - 2021/09/24/revised PY - 2021/10/04/accepted PY - 2021/10/13/entrez PY - 2021/10/14/pubmed PY - 2021/10/21/medline KW - COVID-19 KW - NF-kappaB KW - SARS-CoV-2 KW - adenoviral vector KW - platelet factor 4 (PF4) KW - spike protein KW - thrombocytopenia KW - thrombosis KW - vaccination KW - vaccine-induced immune thrombotic thrombocytopenia (VITT) JF - International journal of molecular sciences JO - Int J Mol Sci VL - 22 IS - 19 N2 - Novel coronavirus SARS-CoV-2 has resulted in a global pandemic with worldwide 6-digit infection rates and thousands of death tolls daily. Enormous efforts are undertaken to achieve high coverage of immunization to reach herd immunity in order to stop the spread of SARS-CoV-2 infection. Several SARS-CoV-2 vaccines based on mRNA, viral vectors, or inactivated SARS-CoV-2 virus have been approved and are being applied worldwide. However, the recent increased numbers of normally very rare types of thromboses associated with thrombocytopenia have been reported, particularly in the context of the adenoviral vector vaccine ChAdOx1 nCoV-19 from Astra Zeneca. The statistical prevalence of these side effects seems to correlate with this particular vaccine type, i.e., adenoviral vector-based vaccines, but the exact molecular mechanisms are still not clear. The present review summarizes current data and hypotheses for molecular and cellular mechanisms into one integrated hypothesis indicating that coagulopathies, including thromboses, thrombocytopenia, and other related side effects, are correlated to an interplay of the two components in the vaccine, i.e., the spike antigen and the adenoviral vector, with the innate and immune systems, which under certain circumstances can imitate the picture of a limited COVID-19 pathological picture. SN - 1422-0067 UR - https://www.unboundmedicine.com/medline/citation/34639132/Coagulopathies_after_Vaccination_against_SARS_CoV_2_May_Be_Derived_from_a_Combined_Effect_of_SARS_CoV_2_Spike_Protein_and_Adenovirus_Vector_Triggered_Signaling_Pathways_ L2 - https://www.mdpi.com/resolver?pii=ijms221910791 DB - PRIME DP - Unbound Medicine ER -